Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 5/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.40 |
| ▸ | SSTR5 | P35346 | 7/20 | 0.40 |
| ▸ | SSTR3 | P32745 | 6/20 | 0.40 |
| ▸ | SSTR2 | P30874 | 4/20 | 0.40 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | TACR2 | P21452 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2797352 | 1.00 | SSTR4 (0.42) | SSTR4MCHR1SSTR5SSTR3SSTR2 | |
| SCHEMBL25414267 | 0.92 | MCHR1 (0.39) | SSTR4MCHR1SSTR5SSTR3SSTR2 | |
| SCHEMBL25412293 | 0.92 | SLC6A2 (0.43) | SSTR4MCHR1SSTR5SSTR3SSTR2 | |
| SCHEMBL25412287 | 0.92 | SLC6A2 (0.43) | SSTR4MCHR1SSTR5SSTR3SSTR2 | |
| SCHEMBL12750132 | 0.89 | TACR2 (0.36) | SSTR4MCHR1SSTR5SSTR3SSTR2 | |
| SCHEMBL2796378 | 0.87 | NT5E (0.39) | NT5ETACR2 | |
| SCHEMBL2796377 | 0.87 | NT5E (0.39) | NT5ETACR2 | |
| SCHEMBL2798123 | 0.86 | TACR2 (0.39) | SSTR4MCHR1SSTR5SSTR3SSTR2 | |
| SCHEMBL13231369 | 0.86 | TACR2 (0.39) | SSTR4MCHR1SSTR5SSTR3SSTR2 | |
| SCHEMBL2798128 | 0.86 | TACR2 (0.39) | SSTR4MCHR1SSTR5SSTR3SSTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035479-A1 | FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION | OM PHARMA (CH) | 2013-02-07 | — | — | US | disclosed |
| US-20100168054-A1 | Functionalized Beta 1,6 Glucosamine Disaccharides and Process for Their Preparation | OM PHARMA (CH) | 2010-07-01 | — | — | US | disclosed |
| EP-2106403-A2 | FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION | OM Pharma (CH) | 2009-10-07 | — | — | EP | disclosed |
| WO-2008059035-A2 | FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION | OM PHARMA (CH) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035479-A1 | FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION | FUT6, FUT5, B3GNT2 | SSTR4 304/4885MCHR1 2487/4885SSTR5 310/4885 |
| US-20100168054-A1 | Functionalized Beta 1,6 Glucosamine Disaccharides and Process for Their Preparation | FUT6, FUT5, B3GNT2 | SSTR4 304/4885MCHR1 2487/4885SSTR5 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.